Candidate Drug Designated
Medivir has reached a milestone in its HIV NNRTI research program and has now designated a clinical Candidate Drug (CD); MIV-170. Designation of a CD means that the project enters the preclinical development phase, which is the stage immediately prior to clinical trials. However, as communicated in December 2005, Medivir has the ambition of divesting or outlicensing its HIV, HBV and shingles polymerase projects through its subsidiary Medivir HIV Franchise AB. Accordingly, Medivir does not intend to invest additional internal resources in MIV-170. MIV-170 belongs to the NNRTI class of drugs,